Yanai Masaaki, Sakamoto Tomohiro, Uetani Naoki, Nonaka Takafumi, Nakada Tatsuya, Matsuoka Shuichi, Moriyama Shiro, Teruya Yasuhiko, Funaki Yoshihiro, Harada Tomoya, Kinoshita Naoki, Yamaguchi Kosuke, Kodani Masahiro, Yamasaki Akira
Division of Respiratory Medicine and Rheumatology, Tottori University Hospital, Japan.
Cancer Center, Tottori University Hospital, Japan.
Intern Med. 2025 Aug 15;64(16):2478-2483. doi: 10.2169/internalmedicine.4877-24. Epub 2025 Feb 1.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are highly effective against EGFR-mutant non-small-cell lung carcinoma but can cause serious adverse events, such as interstitial lung disease (ILD). Treatment strategies for osimertinib-induced ILD are not well established. Cytotoxic anticancer drugs are considered first, although several cases of successful rechallenge with EGFR-TKIs have been reported. We herein report a 67-year-old woman with symptomatic osimertinib-induced ILD who was switched to afatinib and later rechallenged with osimertinib and corticosteroids. Neither treatment resulted in ILD relapse, suggesting that these may be viable treatment options when alternative treatments are limited.
表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）对EGFR突变的非小细胞肺癌具有高度疗效，但可引起严重不良事件，如间质性肺病（ILD）。奥希替尼诱导的ILD的治疗策略尚未完全确立。细胞毒性抗癌药物被视为首选，尽管已有几例成功再次使用EGFR-TKIs的报道。我们在此报告一名67岁有症状的奥希替尼诱导的ILD女性患者，该患者改用阿法替尼，后来再次使用奥希替尼和皮质类固醇。两种治疗均未导致ILD复发，这表明当替代治疗有限时，这些可能是可行的治疗选择。
